The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up von Kurtovic-Kozaric, Amina, Islamagic, Erna, Komic, Hana, Bilalovic, Nurija, Eminovic, Izet, Burekovic, Adnan, Uzunovic, Amna, Kurtovic, Sabira

Volltext

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma von Collins, Graham P., Eyre, Toby A., Schmitz‐Rohmer, Debora, Townsend, William, Popat, Rakesh, Giulino‐Roth, Lisa, Fields, Paul A., Krasniqi, Fatime, Soussain, Carole, Stathis, Anastasios, Andjelkovic, Nebojsa, Cunningham, David, Mandic, Danijela, Radulovic, Sinisa, Tijanic, Ivan, Horowitz, Netanel A., Kurtovic, Sabira, Schorb, Elisabeth, Schmidt, Christian, Dimitrijević, Saša, Dreyling, Martin

Volltext

Real-World Management of Chronic Myeloid Leukemia in Bosnia and Herzegovina: Treatment Patterns, Molecular Monitoring, and Outcomes von Kurtovic-Kozaric, Amina, Islamagic, Erna, Hasic, Azra, Mehinovic-Cavcic, Lejla, Komic, Hana, Kurtovic, Sabira

Volltext

Long term efficacy of nilotinib as front- and second-line therapy in Bosnia and Herzegovina: Real life experience von Kozaric, Amina Kurtovic, Islamagic, Erna, Beslija, Semir, Kurtovic, Sabira, Mehinovic, Lejla, Hasic, Azra

Volltext

The Comparison of Efficacy Between Generic and Branded Imatinib in Achievement of Overall Survival and Cytogenetic Responses in CML Patients in Bosnia and Herzegovina von Kozaric, Amina Kurtovic, Islamagic, Erna, Radich, Jerald P., Suljovic Hadzimesic, Emina, Hasic, Azra, Kurtovic, Sabira

Volltext

The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia von Islamagic, Erna, Hasic, Azra, Kurtovic, Sabira, Suljovic Hadzimesic, Emina, Mehinovic, Lejla, Kozaric, Mirza, Kurtovic-Kozaric, Amina

Volltext

The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients von Kurtovic‐Kozaric, Amina, Hasic, Azra, Radich, Jerald P., Bijedic, Vildan, Nefic, Hilada, Eminovic, Izet, Kurtovic, Sabira, Colakovic, Ferida, Kozaric, Mirza, Vranic, Semir, Bovan, Nada S.

Volltext

Clinical Outcomes of CML Patients After Delayed Start of Nilotinib Treatment von Islamagic, Erna, Hasic, Azra, Kurtovic, Sabira, Suljevic, Damir, Kozaric, Mirza, Eminovic, Izet, Kurtovic-Kozaric, Amina

Volltext

Long-term outcome of GIST patients treated with delayed imatinib therapy von Kurtovic-Kozaric, Amina, Kugic, Amina, Hasic, Azra, Beslija, Semir, Ceric, Timur, Pasic, Anes, Vranic, Semir, Kopric, Dijana, Iljazovic, Ermina, Todorovic Barbuscia, Jelena, Kozaric, Mirza, Ibisevic, Nermina, Keskic, Leila, Kurtovic, Sabira

Volltext

The effects of delayed imatinib mesylate treatment on outcome in patients with GIST von Kozaric, Amina Kurtovic, Kugic, Amina, Kurtovic, Azra, Beslija, Semir, Ceric, Timur, Pasic, Anes, Vranic, Semir, Kozaric, Mirza, Kopric, Dijana, Iljazovic, Ermina, Todorovic Baruscia, Jelena, Ibisevic, Nermina, Kurtovic, Sabira

Volltext

Lack of Access to Targeted Cancer Treatment Modalities in the Developing World in the Era of Precision Medicine: Real-Life Lessons From Bosnia von Kurtovic-Kozaric, Amina, Vranic, Semir, Kurtovic, Sabira, Hasic, Azra, Kozaric, Mirza, Granov, Nermir, Ceric, Timur

Volltext

A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina von Kurtovic-Kozaric, Amina, Islamagic, Erna, Asic, Adna, Mehinovic-Cavcic, Lejla, Besic, Larisa, Sahinbegovic, Hana, Komic, Hana, Kurtovic, Sabira, Burazerovic, Lejla

Volltext

The Three Year Follow-up of CML Patients Treated with First-line Generic and First-line Branded Imatinib in Bosnia and Herzegovina von Islamagic, Erna

Volltext

The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients von Islamagic, Erna, Ms, Hasic, Azra, MD, Kurtovic, Sabira, MD, Hadzimesic, Emina Suljovic, MD, Mehinovic, Lejla, Ms, Kozaric, Mirza, MD, Kurtovic-Kozaric, Amina, PhD

Volltext

The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy von Wenger, Michael K., Foa, Robin, Arcaini, Luca, Vranovský, Andrej, Ivanova, Valentina, Guy, Van Hazel, Kurtovic, Sabira, Durán, Soledad, McKechnie, Stephen, Thurley, Daniel

Volltext